Concepts (98)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 3 | 2025 | 35 | 1.910 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 2 | 2025 | 35 | 0.970 |
Why?
|
| Optic Neuritis | 1 | 2025 | 34 | 0.880 |
Why?
|
| Craniocerebral Trauma | 1 | 2025 | 138 | 0.830 |
Why?
|
| Autoantibodies | 3 | 2025 | 458 | 0.820 |
Why?
|
| Blood Pressure | 1 | 2025 | 1402 | 0.630 |
Why?
|
| Encephalitis | 3 | 2024 | 118 | 0.570 |
Why?
|
| Clonidine | 1 | 2018 | 33 | 0.560 |
Why?
|
| Ischemic Postconditioning | 1 | 2017 | 5 | 0.560 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 1 | 2020 | 303 | 0.550 |
Why?
|
| Syncope | 1 | 2018 | 51 | 0.550 |
Why?
|
| Receptors, Neurokinin-1 | 1 | 2017 | 4 | 0.540 |
Why?
|
| Neurokinin-1 Receptor Antagonists | 1 | 2017 | 5 | 0.540 |
Why?
|
| Rett Syndrome | 1 | 2020 | 289 | 0.530 |
Why?
|
| Hypertension | 1 | 2025 | 1397 | 0.510 |
Why?
|
| Ataxia | 1 | 2017 | 177 | 0.490 |
Why?
|
| Antihypertensive Agents | 1 | 2018 | 430 | 0.450 |
Why?
|
| Motor Activity | 1 | 2017 | 521 | 0.440 |
Why?
|
| Opioid-Related Disorders | 1 | 2017 | 286 | 0.420 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2017 | 300 | 0.420 |
Why?
|
| Cognition | 1 | 2017 | 811 | 0.380 |
Why?
|
| Hashimoto Disease | 2 | 2024 | 29 | 0.250 |
Why?
|
| Mutation | 1 | 2020 | 6247 | 0.250 |
Why?
|
| Receptors, Opioid, delta | 2 | 2017 | 12 | 0.240 |
Why?
|
| Dynorphins | 2 | 2016 | 10 | 0.240 |
Why?
|
| Encephalitis, Herpes Simplex | 1 | 2025 | 13 | 0.240 |
Why?
|
| Receptors, Opioid, mu | 2 | 2017 | 31 | 0.240 |
Why?
|
| Acute Pain | 2 | 2017 | 17 | 0.240 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2025 | 36 | 0.230 |
Why?
|
| Retrospective Studies | 5 | 2025 | 17367 | 0.220 |
Why?
|
| Spin Labels | 1 | 2023 | 21 | 0.200 |
Why?
|
| Dexamethasone | 1 | 2024 | 274 | 0.200 |
Why?
|
| Status Epilepticus | 1 | 2024 | 157 | 0.190 |
Why?
|
| Mice, Inbred ICR | 3 | 2017 | 152 | 0.190 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2023 | 149 | 0.190 |
Why?
|
| B-Lymphocytes | 1 | 2024 | 543 | 0.180 |
Why?
|
| Male | 10 | 2025 | 64951 | 0.170 |
Why?
|
| Brain Diseases | 1 | 2023 | 308 | 0.170 |
Why?
|
| Diagnosis, Differential | 1 | 2025 | 1966 | 0.160 |
Why?
|
| Electroencephalography | 1 | 2024 | 908 | 0.150 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2017 | 1224 | 0.150 |
Why?
|
| Narcotic Antagonists | 2 | 2016 | 110 | 0.140 |
Why?
|
| Adolescent | 3 | 2025 | 20530 | 0.140 |
Why?
|
| Case-Control Studies | 1 | 2025 | 3415 | 0.140 |
Why?
|
| Disease Models, Animal | 3 | 2017 | 4688 | 0.140 |
Why?
|
| Seizures | 1 | 2023 | 895 | 0.140 |
Why?
|
| Child | 4 | 2025 | 25758 | 0.140 |
Why?
|
| Nociceptive Pain | 1 | 2017 | 5 | 0.140 |
Why?
|
| Substance P | 1 | 2017 | 37 | 0.130 |
Why?
|
| Ventral Tegmental Area | 1 | 2017 | 48 | 0.130 |
Why?
|
| Morphine | 1 | 2017 | 85 | 0.130 |
Why?
|
| Receptors, Opioid, kappa | 1 | 2016 | 23 | 0.130 |
Why?
|
| Humans | 9 | 2025 | 132093 | 0.130 |
Why?
|
| Reward | 1 | 2017 | 116 | 0.120 |
Why?
|
| Analgesics | 1 | 2017 | 127 | 0.120 |
Why?
|
| Gene Knockdown Techniques | 1 | 2017 | 397 | 0.120 |
Why?
|
| Dopamine | 1 | 2017 | 253 | 0.120 |
Why?
|
| Biomarkers | 1 | 2025 | 3403 | 0.120 |
Why?
|
| Receptors, Bradykinin | 1 | 2014 | 4 | 0.110 |
Why?
|
| CRISPR-Cas Systems | 1 | 2017 | 293 | 0.110 |
Why?
|
| Female | 6 | 2025 | 70715 | 0.110 |
Why?
|
| Enkephalins | 1 | 2013 | 19 | 0.100 |
Why?
|
| Fentanyl | 1 | 2013 | 56 | 0.100 |
Why?
|
| Spinal Cord | 1 | 2014 | 276 | 0.100 |
Why?
|
| Child, Preschool | 2 | 2025 | 14719 | 0.100 |
Why?
|
| Escherichia coli | 1 | 2017 | 995 | 0.090 |
Why?
|
| Chronic Pain | 1 | 2013 | 148 | 0.090 |
Why?
|
| Brain | 1 | 2023 | 3198 | 0.090 |
Why?
|
| Animals | 5 | 2017 | 34912 | 0.080 |
Why?
|
| Analgesics, Opioid | 1 | 2013 | 470 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 4757 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2025 | 13015 | 0.060 |
Why?
|
| Mice | 3 | 2017 | 18535 | 0.060 |
Why?
|
| Phenotype | 2 | 2025 | 4539 | 0.050 |
Why?
|
| Glutamate Decarboxylase | 1 | 2024 | 42 | 0.050 |
Why?
|
| Injections, Spinal | 1 | 2024 | 136 | 0.050 |
Why?
|
| Rats | 3 | 2016 | 3606 | 0.050 |
Why?
|
| Lymphocyte Depletion | 1 | 2024 | 125 | 0.050 |
Why?
|
| Structure-Activity Relationship | 2 | 2016 | 590 | 0.050 |
Why?
|
| Rituximab | 1 | 2024 | 167 | 0.050 |
Why?
|
| Oligodendroglia | 1 | 2023 | 78 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 1670 | 0.040 |
Why?
|
| Syndrome | 1 | 2023 | 1173 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2025 | 749 | 0.040 |
Why?
|
| Aged | 1 | 2018 | 21456 | 0.040 |
Why?
|
| Cricetulus | 1 | 2016 | 93 | 0.030 |
Why?
|
| Guinea Pigs | 1 | 2016 | 161 | 0.030 |
Why?
|
| CHO Cells | 1 | 2016 | 158 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2024 | 893 | 0.030 |
Why?
|
| Radioligand Assay | 1 | 2014 | 25 | 0.030 |
Why?
|
| Pain | 1 | 2016 | 463 | 0.030 |
Why?
|
| Naloxone | 1 | 2013 | 48 | 0.030 |
Why?
|
| Naltrexone | 1 | 2013 | 71 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 153 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2014 | 297 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2024 | 3854 | 0.020 |
Why?
|
| Cell Line | 1 | 2016 | 2724 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 305 | 0.020 |
Why?
|